aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.99−0.25 (-4.77%)
Close on Nov 17, 2026Market cap $489.46MP/E –Yield –
aTYR PHARMA ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
aTYR PHARMA's ebitda for the twelve months ending Jun 30, 2026 was -$63.20M. For fiscal 2025 it was -$76.96M. The highest annual figure on record is -$15.34M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$76.96M | – |
| FY2024 | Dec 31, 2024 | -$67.21M | – |
| FY2023 | Dec 31, 2023 | -$54.33M | – |
| FY2022 | Dec 31, 2022 | -$46.17M | – |
| FY2021 | Dec 31, 2021 | -$33.54M | – |
| FY2020 | Dec 31, 2020 | -$15.34M | – |
| FY2019 | Dec 31, 2019 | -$22.34M | – |
| FY2018 | Dec 31, 2018 | -$32.07M | – |
| FY2017 | Dec 31, 2017 | -$46.43M | – |
| FY2016 | Dec 31, 2016 | -$57.04M | – |
| FY2015 | Dec 31, 2015 | -$46.75M | – |
| FY2014 | Dec 31, 2014 | -$22.73M | – |
| FY2013 | Dec 31, 2013 | -$18.83M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.71M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$26.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.78M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.44M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.40M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.52M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.53M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.61M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.32M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.08M | -451.2% |
| Q4 FY2020 | Dec 31, 2020 | -$4.81M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.38M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.16M | – |
| Q1 FY2020 | Mar 31, 2020 | $2.02M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.34M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.48M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.71M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.78M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.77M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.04M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.04M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.68M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.99M | – |
| Q4 FY2016 | Dec 31, 2016 | -$12.31M | – |
| Q3 FY2016 | Sep 30, 2016 | -$13.64M | – |
See a number that looks wrong?